Biofocus DPI has extended its drug discovery agreement with Eli Lilly and Company until the end of 2009.
Under the terms of the agreement, Biofocus DPI will identify active compounds by screening of Lilly's library compounds.
The agreement extension builds on the collaboration that began in March 2005.
Biofocus DPI has been working with Lilly on discovering new compounds that target specific cellular signal transduction pathways.
With this agreement, Lilly secures continued access to Biofocus DPI's screening and biology expertise to identify potential new target compounds.
